

June 10, 2022

To,

BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
Maharashtra, India
Phone No.: + 91 22 6136 3155
Fax No.: + 91 22 2272 3121; +91 22 2272 3577
Email: corp.relations@bseindia.com

Sub: Disclosure pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011

**Unit: IIFL Finance Limited
Scrip Code: 532636 | ISIN: INE530B01024**

Dear Sir/Madam,

This is to inform you that we have, on June 10 2022, sold (in open market) 16,000,000 (Sixteen Million) equity shares of IIFL Finance Limited, constituting 4.215% of the paid-up share capital of IIFL Finance Limited. The disclosure as required under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 is enclosed.

Kindly take the above on record.

Yours faithfully,

For British International Investment plc (formerly known as CDC Group PLC)



**Authorised Signatory
Maria Largey, Director & Head Financial Services - Equity**

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	IIFL Finance Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	British International Investment plc (formerly known as CDC Group plc)		
Whether the Acquirer belongs to Promoter/ Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
<i>Details of the acquisition/ disposal as follows</i>	<i>Number</i>	<i>% w.r.t. total share/voting capital wherever applicable (*)</i>	<i>% w.r.t. total diluted share/voting capital of the TC (**)</i>
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	29,501,587 equity shares	7.772%	7.772%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	29,501,587 equity shares	7.772%	7.772%
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	16,000,000 equity shares	4.215%	4.215%

b) VRs acquired/sold otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-
d) Shares encumbered/ invoked/ released by the Acquirer	-	-	-
e) Total (a+b+c+/-d)	16,000,000 equity shares	4.215%	4.215%
After the acquisition/sale, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	13,501,587 equity shares	3.557%	3.557%
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
e) Total (a+b+c+d)	13,501,587 equity shares	3.557%	3.557%
Mode of acquisition/ sale (e.g. open market /off market/ public issue / rights issue / preferential allotment / inter-se transfer, etc.)	Sale of equity shares in open market		

Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	June 10, 2022
Equity share capital / total voting capital of the TC before the said acquisition/sale	379,598,711 equity shares having a face value of INR 2 each (As per shareholding pattern for quarter ended March 2022)
Equity share capital/ total voting capital of the TC after the said acquisition/sale	379,598,711 equity shares having a face value of INR 2 each (As per shareholding pattern for quarter ended March 2022)
Total diluted share/voting capital of the TC after the said acquisition/sale	379,598,711 equity shares having a face value of INR 2 each (As per shareholding pattern for quarter ended March 2022)

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the Authorised Signatory

For British International Investment (Formerly CDC Group PLC)

Name: Maria Largey, Director & Head of Financial Services - Equity

Designation: Authorised Signatory

Place: London

Date: 10 June 2022